Privia Health Group, Inc. (PRVA)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$20.66-0.05%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
Broken: Primary pillar broken — Operating income improves by at least 15% annually: operating income growth not reported vs 15.0% target.
Privia Health grows revenue about 26% yearly, driven by new providers and same-store growth. Profit rose 42% in Q1 2026, showing better cost control. The company reaffirmed its revenue target near $3.15 billion for 2025. The stock trades at a premium but reflects justified growth expectations.
High valuation risks a correction if growth slows. Operating income gains could stall if cost pressures rise. Recent board member departure may signal governance concerns.
The price is about 17% above our fair value near $23, reflecting analyst expectations of 12% revenue growth. We see the company delivering above this but valuation leaves limited upside.
Breaks if: Operating income growth falls below 15% in FY26
Enhance operating income through cost management and efficiency improvements.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is characterized as a durable compounder, given its stable management and strong recent financial performance. However, the current thesis is mixed due to recent changes in sentiment and the potential for execution challenges.
The market currently prices PRVA at a premium compared to peers, reflecting a justified valuation despite some fragility in execution quality. The expectations gap suggests that investors anticipate continued strong performance, but this is not fully guaranteed.
Management is focused on expanding revenue growth and improving operating income, with recent results showing strong year-over-year increases. However, cash flow from operations remains mixed, indicating some uncertainty in this area.
The thesis hinges on several factors, including the ability of management to maintain guidance and the overall health of the job market. Additionally, performance from sector bellwethers could influence PRVA's momentum in the healthcare space.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the view of strong revenue growth potential. Rising guidance indicates that the company is on track to expand its revenue. There are no new threats to the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: YoY revenue growth falls below 12% in FY26
Continue to grow revenue through organic provider growth, new provider additions, and increased practice collections.
Stated as a priority in 4 of last 4 quarters. Revenue grew from $521.2M in 2025-Q2 to $632.6M in 2026-Q2 (+21.4% YoY). Full-year 2026 revenue guidance was raised to $2.35-$2.45B, reflecting management's delivery on growth targets and continued momentum.
“2Q'26 revenue of $632.6M, +21.4% from 2Q'25; full-year 2026 guidance raised for all key financial metrics”
“Total revenue $603.8M, +25.8% YoY; continued strength in same-store growth and new provider additions”
“Full-year 2025 revenue $2.12B, +22.3% YoY; all operating and financial metrics at or above high end of guidance”
“Management focused on organic provider growth and expanding addressable market”
Breaks if: Revenue guidance falls below $3.0B for 2025
Continue to grow revenue through organic provider growth, new provider additions, and increased practice collections.
Stated as a priority in 4 of last 4 quarters. Revenue grew from $521.2M in 2025-Q2 to $632.6M in 2026-Q2 (+21.4% YoY). Full-year 2026 revenue guidance was raised to $2.35-$2.45B, reflecting management's delivery on growth targets and continued momentum.
“2Q'26 revenue of $632.6M, +21.4% from 2Q'25; full-year 2026 guidance raised for all key financial metrics”
“Total revenue $603.8M, +25.8% YoY; continued strength in same-store growth and new provider additions”
“Full-year 2025 revenue $2.12B, +22.3% YoY; all operating and financial metrics at or above high end of guidance”
“Management focused on organic provider growth and expanding addressable market”
Overall, PRVA's fundamentals are strong, but the investment thesis is sensitive to external market conditions and management execution. Not investment advice.